2022 American Transplant Congress

TOPIC: Clinical Science » Liver » 54 - Liver: Immunosuppression and Rejection

Acute Cellular Rejection in Liver Transplant Recipients Following Vaccination Against Covid-19
R. Sarwar¹, O. Adeyi², N. Lim¹
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
R. A. Helmick, S. Naik, C. Eymard, J. Eason, J. Vanatta
Impact of Induction Immunosuppression on Renal Recovery in Adult Liver Transplant Recipients – A Single Center Experience
T. Zurick¹, D. Bruno², D. Kumar³, R. Winstead¹, C. Song¹, A. Brown¹, S. Sterling¹, I. Yakubu¹
Induction Immunosuppression in ABO-Incompatible Liver Transplant Recipients
S. Shaikh¹, I. Hasan¹, N. Kaur²
Is a Single Dose of Steroids in Adult Living Donor Liver Transplant Safe? – A Cohort Analysis
M. Nunez, C. Praglin, A. M. Torres, E. Agudelo, H. Braun, C. Huang, S. Syed, J. Roberts, G. Roll
Phase I/ii Car-Treg Cell Therapy Clinical Trial To Induce Long-term Tolerance In Liver Transplant Patients
A. Sanchez-Fueyo¹, A. Taylor¹, D. Collin², C. Nathalie², S. Chris², M. Martinez-Llordella², N. Belmonte², I. McGill², D. Hartl²
Recipient and Center Factors Associated with Immunosuppression Practice Beyond the First Year After Liver Transplantation
T. Bittermann¹, D. Goldberg²